Mme. Irène Joliot-Curie
نویسندگان
چکیده
منابع مشابه
Cancers du sein bilatéraux synchrones et grossesse a l'institut Joliot Curie de Dakar (Sénégal)
To describe our diagnostic and therapeutic strategy against synchronous, bilateral breast cancer during the pregnancy. Gestational age at diagnosis of cancer was 7; 21 and 25 weeks respectively. Patients had stage IV and IIIA of breast cancer in two and one case respectively. They all received chemotherapy, two cases during pregnancy (6TEC and 3AC) and one case after delivery. Bilateral mastect...
متن کاملGastric Adenocarcinoma: Epidemiology, Diagnosis and Treatment at Joliot Curie Cancer Institute: About 136 Patients
Objectives: To report the epidemiological, diagnostic and therapeutic aspects of gastric adenocarcinoma at the Joliot Curie Cancer Institute. Results: There were about 136 cases of gastric adenocarcinoma over a 13-year period. The sex ratio was 1.125. The mean age was 54.29 years. The main risk factors found were epigastric pain, (9.6%), a history of gastric cancer surgery, (1.5%), and smoking ...
متن کاملThe Discovery of Artificial Radioactivity
Frédéric Joliot was born in Paris on 19th March 1900. His older brother was killed in the first few days of the 1914-1918 war. Frédéric joined the École de physique et chimie industrielles in Paris, where he studied physics at the top of his class. In December 1924, director of studies, Paul Langevin, presented him to Marie Curie; he became her personal assistant at the Radium Institute, which ...
متن کاملMME ( membrane metallo - endopeptidase )
Location: 3q25.2 Note: Membrane metallo-endopeptidase (MME) is a 100-kD type II transmembrane glycoprotein originally described on human acute lymphoblastic leukemia cell lines and therefore it was originally designated as common acute lymphocytic leukemia antigen (CALLA). MME is a neutral endopeptidase that cleaves peptides at the amino side of hydrophobic residues and inactivates several pept...
متن کاملMarie - Christine Alessi and Irène Juhan - Vague
The link between plasminogen activator inhibitor (PAI)-1 and the metabolic syndrome with obesity was established many years ago. Increased PAI-1 level can be now considered a true component of the syndrome. The metabolic syndrome is associated with an increased risk of developing cardiovascular disease, and PAI-1 overexpression may participate in this process. The mechanisms of PAI-1 overexpres...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nature
سال: 1956
ISSN: 0028-0836,1476-4687
DOI: 10.1038/177964a0